CSL (OTCMKTS:CSLLY) Shares Gap Down - Here's What Happened

Key Points

• CSL Limited's stock gapped down from a previous close of $71.22 to open at $67.00, last trading at $68.01 with a volume of 26,617 shares.
• Recent analyst reports have upgraded CSL from a "strong sell" to a "hold" rating, with a consensus rating of "Moderate Buy."
• The company operates in biopharmaceuticals and vaccines, with a significant presence through its segments CSL Behring and CSL Seqirus, focusing on plasma products, gene therapies, and vaccines.

CSL Limited Sponsored ADR (OTCMKTS:CSLLY - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $71.22, but opened at $67.00. CSL shares last traded at $68.01, with a volume of 26,617 shares trading hands.

Analyst Upgrades and Downgrades

CSLLY has been the topic of several research analyst reports. Zacks Research raised CSL from a "strong sell" rating to a "hold" rating in a research note on Monday. Canaccord Genuity Group raised CSL to a "hold" rating in a research note on Monday, October 6th. One equities research analyst has rated the stock with a Strong Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy".

CSL Trading Down 1.6%

The firm has a 50-day moving average of $69.26 and a 200 day moving average of $76.49. The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.